Hematology

The 10 mL ready-to-administer pre-filled syringe in the first FDA-approved pre-filled syringe in this dosing size.

Altuviiio [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl; Sanofi] is high-sustained factor VIII replacement therapy indicated for routine prophylaxis and on-demand treatment to control bleeding episodes and for perioperative management in adults and children with hemophilia A.

Elranatamab is an investigational B-cell maturation antigen CD3-targeted bispecific antibody that may become the next standard of care for multiple myeloma, according to researchers.

Because of CRS and neurologic toxicity risk, the therapy is available through a REMS program.

Paroxysmal nocturnal hemoglobinuria is a rare and life-threatening blood condition.

JNJ-80202135 (nipocalimab) treats hemolytic disease of the fetus and newborn caused by maternal red blood cells.

Isatuximab and daratumumab offer promising treatment options for previously treated multiple myeloma.

Bone marrow transplant could effectively change the brain’s blood vessels from abnormally narrowing.

The trial is the first randomized phase 3 study evaluating the efficacy and safety of ciltacabtagene autoleucel patients with relapsed and lenalidomide-refractory multiple myeloma.

Investigators emphasize the importance of a timely HLH diagnosis and prompt initiation of treatment, as well as close outpatient follow-up to increase patient survival.

Lisocabtagene maraleucel is a CD19-directed CAR T-cell therapy with a 4-1BB costimulatory domain, which enhances the expansion and persistence of the CAR T cells.

The updated label now includes patients with cold agglutinin disease with or without a history of transfusions.

Chronochemotherapy aims to time drug delivery when the body is the least vulnerable to harmful effects, while the cancer cells are the most vulnerable.

At leukapheresis, a low frequency of differentiated CD3+CD27-CD28--T cells can indicate favorable response to CAR T-cell therapy.

Bruton’s tyrosine kinase inhibitor zanubrutinib (Brukinsa; BeiGene USA, Inc) approved for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma.

Soft tissue reconstruction solutions can leverage a patient’s natural healing response.

Study data demonstrate large step forward for this patient population

A retrospective analysis presents unique results for AML treatment.

The mean annualized bleed rate was reduced by 80% from baseline and Factor VIII usage was reduced by 94% in year 3 compared to baseline.

Developments may soon impact clinical practice in hematology and oncology.

Study meets primary and key secondary endpoints, showing clinically meaningful and statistically significant improvements.

A better understanding of the pathogenesis of monoclonal gammopathy of clinical significance would help guide clinicians treating the complex condition.

Although pharmacists possess a wealth of knowledge on AEs, it remains a monumental task to recall the clinical significance of every AE, even with the most commonly used medications.

The FDA granted fidanacogene elaparvovec breakthrough, regenerative medicines advance therapy, and orphan drug designations.

In this special January issue covering ASH and SABCS, we have divided the publication by conference.

Results show possible impact of using Janssen Pharmaceuticals’ ibrutinib in the front-line setting, providing additional data on chronic lymphocytic leukemia therapies.

Targeted therapies have greatly improved patient outcomes over the past 20 years.

Ponatinib could be the first targeted treatment approved in the United States for Philadelphia chromosome-positive acute lymphoblastic leukemia.

Richard T. Maziarz, MD, and a team of investigators assessed average medical costs of allo-HCT throughout a patient’s lifetime and the net monetary savings and value associated with reducing complications.

The FDA clinical reviewer responsible for the approval of this combination therapy discusses the data that led to the approval in May 2022.